Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
A major barrier to research on Parkinson's disease is inaccessibility of diseased tissue for study. One solution is to derive induced pluripotent stem cells from patients and differentiate them into neurons affected by disease. Triplication of SNCA, encoding α-synuclein, causes a fully penetrant, aggressive form of Parkinson's disease with dementia. α-Synuclein dysfunction is the critical pathogenic event in Parkinson's disease, multiple system atrophy and dementia with Lewy bodies. Here we produce multiple induced pluripotent stem cell lines from an SNCA triplication patient and an unaffected first-degree relative. When these cells are differentiated into midbrain dopaminergic neurons, those from the patient produce double the amount of α-synuclein protein as neurons from the unaffected relative, precisely recapitulating the cause of Parkinson's disease in these individuals. This model represents a new experimental system to identify compounds that reduce levels of α-synuclein, and to investigate the mechanistic basis of neurodegeneration caused by α-synuclein dysfunction. Pluripotent stem cells can be generated from the somatic cells of humans and are a useful model to study disease. Here, pluripotent stem cells are made from a patient with familial Parkinson's disease, and the resulting neurons exhibit elevated levels of α-synuclein, recapitulating the molecular features of the patient's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SNCA triplication patient iPSC-derived dopaminergic neurons showed α-synuclein protein over accumulation which was consistent with pathological phenotype in PD patient [35].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Efficient Derivation of Functional Floor Plate Tissue from Human Embryonic Stem Cells
Fasano, C. A., Chambers, S. M., Lee, G., Tomishima, M. J., & Studer, L. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.03.001 · Cited by 209 · cited 1×
“The dual SMAD inhibition protocol has been employed to generate floor plate tissue from human ESC”
MethodRetractedSubramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“A potential solution is to utilize reprogamming technology to generate disease-specific induced pluripotent stem cells (iPSCs”
BackgroundAnalyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190 · cited 1×
“Results were normalized to human TBP using the comparative C(T) metho”
MethodSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Self-citationHighly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620 · cited 1×
“Directed differentiation to dopaminergic neurons We used a feeder-free monolayer culture method of inducing neural differentiation under defined conditions, via dual inhibition of SMAD signallin”
Method
Cited by
Items 101–200 of 484
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“SNCA triplication patient iPSC-derived dopaminergic neurons showed α-synuclein protein over accumulation which was consistent with pathological phenotype in PD patient [35].”
ResultGoh, P. A., Caxaria, S., Casper, C., Rosales, C., Warner, T. T., Coffey, P. J., & Nathwani, A. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081622 · Cited by 67
“An approximately 3-6mm skin punch biopsy was collected by a trained physician under local anaesthetic and fibroblasts generated following previously published protocols [11].”
MethodCellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease
Lázaro, D. F., Pavlou, M. A. S., & Outeiro, T. F. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.05.007 · Cited by 76
Little, D., Luft, C., Mosaku, O., Lorvellec, M., Yao, Z., Paillusson, S., Kriston-Vizi, J., Gandhi, S., Abramov, A. Y., Ketteler, R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27058-0 · Cited by 66
Self-citationKuang, Y., Miki, K., Parr, C., Hayashi, K., Takei, I., Li, J., Iwasaki, M., Nakagawa, M., Yoshida, Y., & Saito, H. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.04.010 · Cited by 65
Xu, X., & Zhong, Z. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.63 · Cited by 73
Induced pluripotent stem cells in Parkinson's disease: scientific and clinical challenges
Xiao, B., Ng, H., Takahashi, R., & Tan, E.-K. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312036 · Cited by 75
Virdi, G. S., Choi, M. L., Evans, J. R., Yao, Z., Athauda, D. S., Strohbuecker, S., Nirujogi, R. S., Wernick, A. I., Pelegrina‐Hidalgo, N., Leighton, C., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00423-7 · Cited by 69
Self-citationMak, S. K., Huang, Y. A., Iranmanesh, S., Vangipuram, M., Sundararajan, R., Nguyen, L., Langston, J. W., & Schüle, B. (2012) · Stem Cells International · doi:10.1155/2012/140427 · Cited by 71
Xiao, Y., Chen, X., Huang, S., Li, G., Mo, M., Zhang, L., Chen, C., Guo, W., Zhou, M., Wu, Z., et al. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14312 · Cited by 66
“Adenovirus expressing a-Syn-RFP may result in rapidly increasing and maintaining high expression levels of a-SynRFP that gradually decrease over time, as higher expression levels of a-synuclein lead to a higher ratio of the transmission (Devine et al. 2011).”
BackgroundMacAskill, M. G., Saif, J., Condie, A., Jansen, M. A., MacGillivray, T., Tavares, A., Fleisinger, L., Spencer, H. L., Besnier, M., Martin, E., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.017 · Cited by 68
Lange, S., Gallagher, M., Kholia, S., Kosgodage, U. S., Hristova, M., Hardy, J., & Inal, J. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061196 · Cited by 69
“Similar changes were also observed for α-synuclein triplication [200] compared to control neurones [193].”
ResultSelf-citationNistor, P., May, P. W., Tamagnini, F., Randall, A. D., & Caldwell, M. A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.050 · Cited by 70
Using iPS Cells toward the Understanding of Parkinson’s Disease
Torrent, R., De Angelis Rigotti, F., Dell'Era, P., Memo, M., Raya, A., & Consiglio, A. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040548 · Cited by 60
“These cells showed enhanced α-syn mRNA and protein levels [30] and increased cell death vulnerability when exposed to oxidative-stress inducers [31].”
BackgroundCorti, S. P., Faravelli, I., Cardano, M., & Conti, L. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1037737 · Cited by 67
TDP-43 induces p53-mediated cell death of cortical progenitors and immature neurons
Vogt, M. A., Ehsaei, Z., Knuckles, P., Higginbottom, A., Helmbrecht, M. S., Kunath, T., Eggan, K. C., Williams, L. A., Shaw, P. J., Wurst, W., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26397-2 · Cited by 66
Self-citationEmanuele, M., & Chieregatti, E. (2015) · Biomolecules · doi:10.3390/biom5020865 · Cited by 70
George, G., Singh, S., Lokappa, S. B., & Varkey, J. (2018) · Genomics · doi:10.1016/j.ygeno.2018.05.005 · Cited by 60
Srikanth, P., & Young-Pearse, T. L. (2014) · Journal of Neurogenetics · doi:10.3109/01677063.2014.881358 · Cited by 57
“…neurons ND Soldner et al., 2011 2011 1 SCNA triplication, 1 wt Dopaminergic neurons Expression of α -synuclein and other triplicated genes Devine et al., 2011 2011 1 SCNA triplication, 1 wt Dopaminergic neurons α -Synuclein expression, oxidative stress, peroxideinduced cell death…”
BackgroundAlhebshi, A., Odawara, A., Gotoh, M., & Suzuki, I. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.09.049 · Cited by 59
Back and forth in time: Directing age in iPSC-derived lineages
Cornacchia, D., & Studer, L. (2017) · Brain Research · doi:10.1016/j.brainres.2015.11.013 · Cited by 56
“…certain stressors (Seibler et al., 2011; Woodard et al., 2014; Miller et al., 2013; Soldner et al., 2009; Nguyen et al., 2011; Soldner et al., 2011; Devine et al., 2011; Byers et al., 2011; Sanchez-Danes et al., 2012; Cooper et al., 2012; Imaizumi et al., 2012; Liu et al., 2012; Reinhardt et al.,…”
Crompton, L. A., Byrne, M. L., Taylor, H., Kerrigan, T. L., Bru‐Mercier, G., Badger, J. L., Barbuti, P. A., Jo, J., Tyler, S. J., Allen, S. J., et al. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.08.002 · Cited by 62
Self-citationStem cell-based approach for the treatment of Parkinson's disease.
Goodarzi, P., Aghayan, H. R., Larijani, B. A., Soleimani, M., Dehpour, A. R., Sahebjam, M., Ghaderi, F., & Arjmand, B. (2015) · PubMed Central · Cited by 68
Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease
Beevers, J. E., Caffrey, T. M., & Wade‐Martins, R. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130194 · Cited by 56
Probing disorders of the nervous system using reprogramming approaches
Ichida, J. K., & Kiskinis, E. (2015) · The EMBO Journal · doi:10.15252/embj.201591267 · Cited by 50
Fanizza, F., Campanile, M., Forloni, G., Giordano, C., & Albani, D. (2022) · Journal of Tissue Engineering · doi:10.1177/20417314221095339 · Cited by 58
How induced pluripotent stem cells are redefining personalized medicine
Ferreira, L. M. R., & Mostajo-Radji, M. A. (2013) · Gene · doi:10.1016/j.gene.2013.02.037 · Cited by 59
Sen, T., & Thummer, R. P. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00564-w · Cited by 55
“The authors used midbrain dopaminergic neurons generated from iPSCs obtained from a spontaneous PD patient possessing three copies of the SNCA gene (Devine et al. 2011).”
BackgroundMethodSystems level analysis of sex-dependent gene expression changes in Parkinson’s disease
Tranchevent, L.-C., Halder, R., & Glaab, E. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00446-8 · Cited by 79
Therapeutic Application of Stem Cell Technology toward the Treatment of Parkinson’s Disease
Nishimura, K., & TAKAHASHI, J. C. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00929 · Cited by 57
Ulusoy, A., & Monte, D. A. D. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8329-y · Cited by 55
“One example of a novel approach is the use of induced pluripotent stem cells isolated from patients with sporadic or genetic parkinsonism [96].”
BackgroundHargus, G., Ehrlich, M., Hallmann, A.-L., & Kuhlmann, T. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1222-6 · Cited by 60
“Three independent groups reported the derivation of iPS cells from patients with a SNCA triplication [27, 53, 194] (Table S2).”
BackgroundProbing the Origin of the Toxicity of Oligomeric Aggregates of α-Synuclein with Antibodies
Cascella, R., Perni, M., Chen, S. W., Fusco, G., Cecchi, C., Vendruscolo, M., Chiti, F., Dobson, C. M., & Simone, A. D. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00312 · Cited by 52
Single-Cell RNA Sequencing in Parkinson’s Disease
Ma, S., & Lim, S. B. (2021) · Biomedicines · doi:10.3390/biomedicines9040368 · Cited by 62
Deshmukh, R. S., Kovács, K. A., & Dinnyés, A. (2012) · Stem Cells International · doi:10.1155/2012/379569 · Cited by 52
Mahalingam, D., Kong, C. M., Lai, J. K. H., Tay, L. L., Yang, H. H., & Wang, X. (2012) · Scientific Reports · doi:10.1038/srep00592 · Cited by 54
Neural Transcription Factors: from Embryos to Neural Stem Cells
Lee, H.-K., Lee, H., & Moody, S. A. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.0227 · Cited by 57
“tive neural stem cells) (Devine et al., 2011; Tropepe et al., 2001).”
BackgroundChou, S., Tseng, W.-L., Chen, C.-T., Lai, Y.-F., Chien, C., Chang, Y.-L., Lee, H., Wei, Y., & Chiou, S. (2016) · Scientific Reports · doi:10.1038/srep23661 · Cited by 49
Accelerating progress in induced pluripotent stem cell research for neurological diseases
Ito, D., Okano, H., & Suzuki, N. (2012) · Annals of Neurology · doi:10.1002/ana.23596 · Cited by 58
Human disease modeling with induced pluripotent stem cells
Trounson, A. O., Shepard, K. A., & DeWitt, N. D. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.07.004 · Cited by 56
Renner, H., Schöler, H. R., & Bruder, J. M. (2021) · Movement Disorders · doi:10.1002/mds.28775 · Cited by 49
Modeling Keratoconus Using Induced Pluripotent Stem Cells
Joseph, R., Srivastava, O. P., & Pfister, R. R. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19105 · Cited by 48
Nim, S., O’Hara, D. M., Corbi‐Verge, C., Perez‐Riba, A., Fujisawa, K., Kapadia, M., Chau, H., Albanese, F., Pawar, G. N., de Snoo, M. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37464-2 · Cited by 54
“3-RFP (two-tailed nested t-test, t(51) = 4.”
Sison, S. L., Vermilyea, S., Emborg, M. E., & Ebert, A. D. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0893-8 · Cited by 53
Karyopherin abnormalities in neurodegenerative proteinopathies
Pasha, T., Zatorska, A., Sharipov, D., Rogelj, B., Hortobágyi, T., & Hirth, F. (2021) · Brain · doi:10.1093/brain/awab201 · Cited by 53
“Alterations in KPNB1 expression were identified using microarray analysis of tissue material derived from Parkinson’s disease patients with a triplication in the a-syn encoding SNCA gene.(65,135) Lewy body formation triggered by prefibrillary a-syn was found to alter the expression levels of KPNA7 and XPO1/exportin-1.”
BackgroundGene expression in the Parkinson's disease brain
Lewis, P. A., & Cookson, M. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.11.016 · Cited by 48
Self-citationα-Synuclein mutations cluster around a putative protein loop
Kara, E., Lewis, P. A., Ling, H., Proukakis, C., Houlden, H., & Hardy, J. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.04.058 · Cited by 50
Self-citationFrom cell lines to pluripotent stem cells for modelling Parkinson's Disease
Ferrari, E. S., Cardinale, A., Picconi, B., & Gardoni, F. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108741 · Cited by 47
Begum, A. N., Guoynes, C. D., Cho, J., Hao, J., Lutfy, K., & Hong, Y. (2015) · Stem Cell Research · doi:10.1016/j.scr.2015.10.014 · Cited by 47
“…conditions, including motor neuron disease, Niemann-Pick disease (NPD), Huntington disease (HD), Parkinson's disease (PD) and Alzheimer's disease (AD) (Dimos et al., 2008; Park et al., 2008; Yagi et al., 2011; Shi et al., 2012a; Israel et al., 2012; Devine et al., 2011; Jeon et al., 2012).”
BackgroundWhen rejuvenation is a problem: challenges of modeling late-onset neurodegenerative disease
Vera, E., & Studer, L. (2015) · Development · doi:10.1242/dev.120667 · Cited by 43
“…levels, mitochondrial dysfunction and hypersensitivity to toxins such as compounds that trigger mitochondrial stress or ROS (Byers et al., 2011; Devine et al., 2011; Seibler et al., 2011; Soldner et al., 2011; Cooper et al., 2012; Imaizumi et al., 2012; Liu et al., 2012; Sánchez-Danés et al.,…”
BackgroundModeling Parkinson’s Disease Using Patient-specific Induced Pluripotent Stem Cells
Li, H., Jiang, H., Zhang, B., & Feng, J. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181353 · Cited by 50
“Third, increased expression of -synuclein has been observed in iPSC-derived neurons from PD patients with mutations in -synuclein [54, 55], LRRK2 [73, 75], parkin [93, 99], PINK1 [93] or DJ-1 [114].”
BackgroundThe E3 Ubiquitin Ligases TRIM17 and TRIM41 Modulate α-Synuclein Expression by Regulating ZSCAN21
Lassot, I., Mora, S., Lesage, S., Zieba, B. A., Coque, E., Condroyer, C., Bossowski, J. P., Mojsa, B., Marelli, C., Soulet, C., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.002 · Cited by 45
Schlaudraff, F., Gründemann, J., Fauler, M., Dragicevic, E., Hardy, J., & Liss, B. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.016 · Cited by 46
“These findings point to a key role of wild-type SNCA genedosage for death of DA neurons in sporadic PD (Devine et al., 2011b; Eriksen et al., 2005).”
Self-citationAlpha‐synuclein‐associated changes in PINK1‐PRKN‐mediated mitophagy are disease context dependent
Hou, X., Chen, T. H., Koga, S., Bredenberg, J. M., Faroqi, A. H., Delenclos, M., Bu, G., Wszołek, Z. K., Carr, J. A., Ross, O. A., et al. (2023) · Brain Pathology · doi:10.1111/bpa.13175 · Cited by 47
“While it is known that fibroblasts generally have very low expression of SNCA [41, 42], both triplication cells showed more than 5–10 fold increased αsyn protein levels”
BackgroundThe Path from Skin to Brain: Generation of Functional Neurons from Fibroblasts
Abdullah, A. I., Pollock, A., & Sun, T. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8277-6 · Cited by 43
Stem Cells asIn VitroModel of Parkinson's Disease
Martínez‐Morales, P., & Liste, I. (2012) · Stem Cells International · doi:10.1155/2012/980941 · Cited by 51
Sancandi, M., Uysal-Onganer, P., Kraev, I., Mercer, A., & Lange, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082743 · Cited by 41
“Furthermore, in PD iPSC neuronal models, derived from fibroblasts of patients carrying α-synuclein triplication [15], an increase and change in deiminated protein patterns has also been reported [9].”
BackgroundResultInduced Pluripotent Stem Cell Potential in Medicine, Specifically Focused on Reproductive Medicine
Botman, O., & Wyns, C. (2014) · Frontiers in Surgery · doi:10.3389/fsurg.2014.00005 · Cited by 42
Induced pluripotent stem cell technology for modelling and therapy of cerebellar ataxia
Watson, L. M., Wong, M. M. K., & Becker, E. B. E. (2015) · Open Biology · doi:10.1098/rsob.150056 · Cited by 44
Bose, A., & Beal, M. F. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14264 · Cited by 47
“IPSC- derived neurons from patients with SNCA triplication have been generated (Byers et al., 2011; Devine et al., 2011).”
BackgroundApplications of induced pluripotent stem cells in studying the neurodegenerative diseases
Wan, W., Cao, L., Kalionis, B., Xia, S., & Tai, X. (2015) · Stem Cells International · doi:10.1155/2015/382530 · Cited by 40
Ho, G. P. H., Wilkie, E. C., White, A. J., & Selkoe, D. J. (2023) · Science Signaling · doi:10.1126/scisignal.add7220 · Cited by 46
“(D) Comparison of Syt11-wt-FLAG levels in SNCA triplication iNs transduced with Syt11-wt-FLAG and HEK cells transiently transfected with Syt11-wtFLAG.”
BackgroundMethodInfluentialA cellular star atlas: using astrocytes from human pluripotent stem cells for disease studies
Krencik, R., & Ullian, E. M. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00025 · Cited by 40
Payne, N. L., Sylvain, A., O’Brien, C., Herszfeld, D., Sun, G., & Bernard, C. C. A. (2014) · New Biotechnology · doi:10.1016/j.nbt.2014.05.001 · Cited by 45
“Modeling Parkinson’s disease Several groups have now generated hiPSCs from sporadic PD patients [118,119] and familial PD patients with mutations in the genes encoding a-synuclein [120–122], PINK1 [123], LRRK2 [124–126] and Parkin [127,128] (Table 2).”
BackgroundMarotta, N., Kim, S., & Krainc, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1703671 · Cited by 42
Upregulation of Cellular Palmitoylation Mitigates α‐Synuclein Accumulation and Neurotoxicity
Ho, G. P. H., Ramalingam, N., Imberdis, T., Wilkie, E. C., Dettmer, U., & Selkoe, D. J. (2020) · Movement Disorders · doi:10.1002/mds.28346 · Cited by 39
“The SNCA triplication and corrected iPSC lines (AST23) were a generous gift of the Kunath Lab (University of Edinburgh).(31)”
BackgroundCollo, G., Cavalleri, L., Chiamulera, C., & Merlo Pich, E. (2018) · NeuroReport · doi:10.1097/wnr.0000000000001131 · Cited by 37
Chang, K., Lee‐Chen, G., Wu, Y., Chen, Y.-J., Lin, J.-L., Li, M., Chen, I., Lo, Y., Wu, H.-C., & Chen, C. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.01.001 · Cited by 40
Brazdis, R.-M., Alecu, J. E., Marsch, D., Dahms, A., Simmnacher, K., Lörentz, S., Brendler, A., Schneider, Y., Marxreiter, F., Roybon, L., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa039 · Cited by 37
Strategies for modeling aging and age-related diseases
Jothi, D., & Kulka, L. A. M. (2024) · npj Aging · doi:10.1038/s41514-024-00161-5 · Cited by 41
“1) and differentiation by dual inhibition 118 or differentiation by removal of growth factor 119 resulted in DA neurons that exhibited approximately twice the levels of α -synuclein compared to unaffected fi rst-degree relatives 67,118,119 .”
BackgroundKantor, B., O’Donovan, B., & Chiba‐Falek, O. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102635 · Cited by 40
Induced Pluripotent Stem Cell-Based Drug Screening by Use of Artificial Intelligence
Kusumoto, D., Yuasa, S., & Fukuda, K. (2022) · Pharmaceuticals · doi:10.3390/ph15050562 · Cited by 40
“Many reports have shown that disease modeling is successful when using iPSCs, including Alzheimer’s disease (AD) [23,24], Parkinson’s disease [25,26], amyotrophic lateral sclerosis (ALS) [27,28], and schizophrenia [29,30].”
BackgroundThe Role of Rab Proteins in Parkinson’s Disease Synaptopathy
Bellucci, A., Longhena, F., & Spillantini, M. G. (2022) · Biomedicines · doi:10.3390/biomedicines10081941 · Cited by 37
“Moreover, multiplications of the aSyn gene (SNCA) cause the onset of a rare form of early-onset PD with rapid progression [18].”
BackgroundUsing induced pluripotent stem cell neuronal models to study neurodegenerative diseases
Zhang, X., Hu, D., Shang, Y., & Qi, X. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.03.004 · Cited by 38
Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling
Beghini, D. G., Kasai-Brunswick, T. H., & Henriques‐Pons, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042392 · Cited by 42
“The patient’s neurons produced twice the amount of α -synuclein protein compared to the unaffected relative, recapitulating the in vitro PD pathology [31].”
ResultHuman Inducible Pluripotent Stem Cells and Autism Spectrum Disorder: Emerging Technologies
Nestor, M. W., Phillips, A. W., Artimovich, E., Nestor, J. E., Hussman, J. P., & Blatt, G. J. (2016) · Autism Research · doi:10.1002/aur.1570 · Cited by 35
“Due to species differences and other limitations, preclinical results from animal models have not been reliable and do not translate well at the clinical trial stage [Devine et al., 2011; Han et al., 2013].”
BackgroundRyan, B. J., Bengoa‐Vergniory, N., Williamson, M. G., Kirkiz, E., Roberts, R. F., Corda, G., Sloan, M., Saqlain, S., Cherubini, M., Poppinga, J., et al. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.1478-20.2021 · Cited by 40
“We observed dysregulation of REST target genes in both transcriptomic datasets (Devine et al., 2011; Zambon et al., 2019), suggesting REST inhibition (Fig.”
BackgroundInfluentialLin, M., Mackie, P. M., Shaerzadeh, F., Gamble‐George, J., Miller, D. R., Martyniuk, C. J., & Khoshbouei, H. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01203-9 · Cited by 40
Oosterveen, T., Garção, P., Moles-Garcia, E., Soleilhavoup, C., Travaglio, M., Sheraz, S., Peltrini, R., Patrick, K., Labas, V., Combes‐Soia, L., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.09.014 · Cited by 39
“25–35) (Devine et al., 2011) were cultured on Geltrex-coated 6-”
ResultInfluentialHuman Pluripotent Stem Cells: Applications and Challenges in Neurological Diseases
Hibaoui, Y., & Féki, A. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00267 · Cited by 36
NOX-induced oxidative stress is a primary trigger of major neurodegenerative disorders
Zilberter, Y., Tabuena, D. R., & Zilberter, M. Y. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102539 · Cited by 37
“In vitro studies using induced pluripotent stem cell-derived neurons obtained from PD patients (Devine et al., 2011; Zhang et al., 2004) have further demonstrated that oligomeric α -synuclein generates ROS in these cells, independent of mitochondrial activity (Abramov et al., 2020; Deas et al.,…”
Li, W., Chen, S., & Li, J. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.009 · Cited by 38
Ghaffari, L. T., Starr, A., Nelson, A. T., & Sattler, R. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00056 · Cited by 34
“The most common dementia, Alzheimer’s disease (AD), has been examined extensively in patient-derived iPSCs, and these studies been thoroughly reviewed (Devineni et al., 2016; Arber et al., 2017; Robbins and Price, 2017; Tong et al., 2017).”
BackgroundModeling Parkinson’s Disease Using Induced Pluripotent Stem Cells
Hu, X., Mao, C., Fan, L., Luo, H., Hu, Z., Zhang, S., Yang, Z., Zheng, H., Sun, H., Fan, Y., et al. (2020) · Stem Cells International · doi:10.1155/2020/1061470 · Cited by 42
“These iPSC-derived dopaminergic neurons successfully mimicked the PD phenotype of α-synuclein accumulation, which were not detected in the skin fibroblasts from PD patients [20].”
BackgroundIntegrated generation of induced pluripotent stem cells in a low-cost device
Lin, H., Li, Q., Du, Q., Wang, O., Wang, Z., Akert, L., Carlson, M. A., Zhang, C., Subramanian, A., Zhang, C., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.027 · Cited by 36
Recent advances of induced pluripotent stem cells application in neurodegenerative diseases
Amin, N., Tan, X., Ren, Q., Zhu, N., Botchway, B. O. A., Hu, Z., & Fang, M. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109674 · Cited by 39
Collo, G., Mucci, A., Giordano, G. M., Pich, E. M., & Galderisi, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00632 · Cited by 38
“…and uptake of DA, and by electrophysiological signature, e.g., the burst firing typical of native DA neurons of the mammal ventral mesencephalon Frontiers in Neuroscience | www.frontiersin.org 5 June 2020 | Volume 14 | Article 632 (Devine et al., 2011; Kriks et al., 2011; Collo et al., 2018).”
BackgroundAutophagy in α-Synucleinopathies—An Overstrained System
Fellner, L., Gabassi, E., Haybaeck, J., & Edenhofer, F. (2021) · Cells · doi:10.3390/cells10113143 · Cited by 45
Cui, X., Li, X., Zheng, H., Su, Y., Zhang, S., Li, M., Hao, X., Zhang, S., Hu, Z., Xia, Z., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00799-8 · Cited by 41
“Notably, compared to traditional hMLO that aims to mimic the whole midbrain area, the VM-patterned hMLOs are prone to produce more A9 DA neurons, which is essential in PD development molecular pro fi le 55,156 – 158 .”
BackgroundElevated α-synuclein levels inhibit mitophagic flux
Kinnart, I., Manders, L., Heyninck, T., Imberechts, D., Praschberger, R., Schoovaerts, N., Verfaillie, C. M., Verstreken, P., & Vandenberghe, W. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00696-0 · Cited by 34
Vásquez-Jiménez, J. M., Arévalo‐Herrera, M., Henao, J., Molina-Gómez, K., Arce-Plata, M. I., Vallejo, A. F., & Herrera, S. V. (2016) · Malaria Journal · doi:10.1186/s12936-016-1124-x · Cited by 35
Techno-Economic Analysis of Automated iPSC Production
Nießing, B., Kiesel, R., Herbst, L., & Schmitt, R. H. (2021) · Processes · doi:10.3390/pr9020240 · Cited by 32
Using iPSC ‐derived human DA neurons from opioid‐dependent subjects to study dopamine dynamics
Yang, S., Filichia, E., Shick, E. A., Preston, K. L., Phillips, K. A., Cooperman, L., Lin, Z., Tesar, P. J., Hoffer, B. J., & Luo, Y. (2016) · Brain and Behavior · doi:10.1002/brb3.491 · Cited by 33
“…of addiction and toxicity of drugs. iPS cell technologies have been used to examine the mechanisms of multiple disorders including amyotrophic lateral sclerosis (ALS) (Egawa et al. 2012), Huntington’s disease (HD) (HD iPSC Consortium 2012), and Parkinson’s disease (PD) (Devine et al. 2011).”
Modeling Neurovascular Disorders and Therapeutic Outcomes with Human-Induced Pluripotent Stem Cells
Bosworth, A. M., Faley, S. L., Bellan, L. M., & Lippmann, E. S. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2017.00087 · Cited by 34
Generation of defined neural populations from pluripotent stem cells
McComish, S. F., & Caldwell, M. A. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0214 · Cited by 34
A monolayer hiPSC culture system for autophagy/mitophagy studies in human dopaminergic neurons
Stathakos, P., Jiménez-Moreno, N., Crompton, L. A., Nistor, P., Badger, J. L., Barbuti, P. A., Kerrigan, T. L., Randall, A. D., Caldwell, M. A., & Lane, J. D. (2020) · Autophagy · doi:10.1080/15548627.2020.1739441 · Cited by 32
Using induced pluripotent stem cells for modeling Parkinson’s disease
Ke, M., Chong, C., & Su, H. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i9.634 · Cited by 32
Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases
Trudler, D., Ghatak, S., & Lipton, S. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158196 · Cited by 31
“Additionally, fPD patient-derived hiPSC-DA neurons bearing SNCA, LRRK2, or Parkin mutations manifested disrupted synaptogenesis, synaptic transmission, and neurotransmitter release [133,149,150].”
BackgroundFocused Ultrasound Stimulation as a Neuromodulatory Tool for Parkinson’s Disease: A Scoping Review
Lee, K. S., Clennell, B., Steward, T. G. J., Gialeli, A., Llana, O. C., & Whitcomb, D. J. (2022) · Brain Sciences · doi:10.3390/brainsci12020289 · Cited by 30
“TH is the rate-limiting enzyme responsible for catalysing the conversion of the amino acid L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA), which is eventually transformed to dopamine [63].”
BackgroundD’Amico, R., Gugliandolo, E., Siracusa, R., Cordaro, M., Genovese, T., Peritore, A. F., Crupi, R., Interdonato, L., Paola, D. D., Cuzzocrea, S., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10051073 · Cited by 38
Metadata
- Authors
- Devine, M. J., Ryten, M., Vodicka, P., Thomson, A. J., Burdon, T., Houlden, H., Cavaleri, F., Nagano, M., Drummond, N. J., Taanman, J.-W., Schapira, A. H., Gwinn, K., Hardy, J., Lewis, P. A., & Kunath, T.
- Affiliations
- MRC Centre for Regenerative Medicine (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Roslin Institute (GB)
- University of Tsukuba (JP)
- Baylor College of Medicine (US)
- Corresponding author
- Devine, Michael J.
- Kunath, Tilo
- ORCID
- Venue
- Nature Communications
- Published
- 2011-08-23
- Volume
- 2
- Issue
- 1
- Pages
- 440-440
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3265381
- OpenAlex
- W1985010554
- Cited by
- 486
- References
- 61
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 27 · 2023: 25 · 2022: 40 · 2021: 26 · 2020: 43 · 2019: 24 · 2018: 46 · 2017: 34 · 2016: 34 · 2015: 38 · 2014: 29 · 2013: 32 · 2012: 48
- FWCI
- 22.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- ASEP (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- University of Dundee
- Wellcome Trust (089698)
- Parkinson's UK (K-0911, G-4046, G-0907, F1002), F-0902)
- Brain Research Trust
- University of Sheffield
- Medical Research Council (MC_G1000735)
- Biotechnology and Biological Sciences Research Council (BBS/E/R/00001627, BBS/E/R/00001601)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, induced pluripotent stem cells, alpha-synuclein, SNCA triplication, familial Parkinson's disease, midbrain dopaminergic neurons, disease modeling, neurodegeneration, multiple system atrophy, dementia with Lewy bodies, alpha-synuclein overexpression
- MeSH terms
- Cell Differentiation, Cells, Cultured, Humans, Neurons, Parkinson Disease, Gene Dosage, alpha-Synuclein, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.